Rapid Dose Therapeutics Corp. News Releases

Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market

Thu, 05 Mar 2026 10:08:00 -0500

Burlington, Ontario--(Newsfile Corp. - March 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips.The patent, titled "Nicotine Bilayer Oral Film and Process for Preparation Thereof," has been granted by the Indian Patent Office under Patent Number IN 582202,...

Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform

Mon, 23 Feb 2026 06:12:00 -0500

Burlington, Ontario--(Newsfile Corp. - February 23, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company focused on innovative drug delivery solutions, today provided an update on its ongoing cannabinoid research initiatives and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform.Independent research led by colleagues Dr. Patrick Neary of the Faculty of Kinesiology & Health...

Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors

Wed, 11 Feb 2026 11:21:00 -0500

Burlington, Ontario--(Newsfile Corp. - February 11, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that its common shares are now trading in the United States on the OTCQB Venture Market under the ticker symbol RDTCF.The OTCQB listing expands Rapid Dose Therapeutics' presence in the U.S. capital markets by increasing accessibility and visibility for...

Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment

Tue, 10 Feb 2026 07:00:00 -0500

Burlington, Ontario--(Newsfile Corp. - February 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") , a Canadian biotechnology company focused on innovative drug delivery solutions, today announced the commercial launch of its Entourage Phytolab co-branded QuickStrip™ medical cannabis oral thin film in Brazil following regulatory approval for both manufacturing and distribution by Brazil's National Health Regulatory Agency (ANVISA).This milestone...

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Mon, 05 Jan 2026 17:30:00 -0500

Burlington, Ontario--(Newsfile Corp. - January 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on December 31, 2025. The Company expects to issue the Common Shares no later than January 15, 2026.The Notes were issued as a...

Rapid Dose Completes Extension to Promissory Notes

Mon, 08 Dec 2025 19:19:00 -0500

Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it has extended the maturity date of its outstanding secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing") which closed in 2023. The Notes had a maturity date of November 30, 2025, and the Company extended the maturity date for one year, to November 30, 2026.The Financing was an offering of...

Rapid Dose Announces Extension to Promissory Notes

Fri, 28 Nov 2025 20:14:00 -0500

Burlington, Ontario--(Newsfile Corp. - November 28, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it intends to extend the maturity date of its outstanding secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing") which closed in 2023. The Notes have a maturity date of November 30, 2025, and the Company intends to extend the maturity date for one year, to November 30, 2026.The Financing was an...

Rapid Dose Therapeutics Releases Nicotine Business Update and Extends Collaboration with International Nicotine Partner

Mon, 20 Oct 2025 08:48:00 -0400

Seven-month extension valued at up to approximately $1.8 million CAD supports further evaluation as RDT advances broader commercialization initiatives for NicStrip(TM) Burlington, Ontario--(Newsfile Corp. - October 20, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company developing innovative drug delivery solutions through its QuickStrip™ platform, today issued a comprehensive update on its nicotine strategy, including the extension of its...

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Thu, 02 Oct 2025 16:31:00 -0400

Burlington, Ontario--(Newsfile Corp. - October 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), and consistent with prior quarters, the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on September 30, 2025 under the terms of the Notes. The Company expects...

Rapid Dose Therapeutics Submits QuickStrip(TM) Nicotine Product for Health Canada Approval

Mon, 04 Aug 2025 09:16:00 -0400

Innovative Oral Nicotine Delivery Technology Targets Safer Alternative for Smokers Burlington, Ontario--(Newsfile Corp. - August 4, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company focused on innovative drug delivery technologies, is pleased to announce the submission of a product application to Health Canada for approval of its QuickStrip™ Nicotine products in 1 mg, 2 mg, 3 mg, and 4 mg formats. This regulatory milestone marks a...